Videos

Oncologists explain data from the NADIM II and AEGAN clinical trials investigating treatments for neoadjuvant immunotherapy in resectable NSCLC.

Neoadjuvant Immunotherapy in Resectable NSCLC: The NADIM II and AEGAN Trials

Myung-Ju Ahn, MD, summarizes the role of neoadjuvant immunotherapy in early-stage NSCLC treatment.

The Role of Neoadjuvant Immunotherapy in the Treatment of Resectable NSCLC

Melissa Johnson, MD, and Solange Peters, MD, review the available treatment options for stage I – III non-small cell lung cancer (NSCLC) and how the ESMO guidelines of patient management differ from the NCCN guidelines.

Treatment Options for Early-Stage Non-Small Cell Lung Cancer (NSCLC)

Melissa L. Johnson, MD, program director, Lung Cancer Research, lead, Solid Tumor Immune Effector Cellular Therapy Program, Sarah Cannon Research Institute, discusses new drug approvals for 

 exon 20 insertion mutation–positive non–small cell lung cancer (NSCLC). 

In 2021, 2 new drugs were approved in the metastatic setting for the small subgroup of patients with NSCLC harboring 

 exon 20 insertion mutations, Johnson says. These new approvals included amivantamab-vmjw (Rybrevant), which is given intravenously with a loading dose followed by once every 2 weeks, and mobocertinib (Exkivity), which is given orally daily, Johnson explains.

Notably, these drugs have differing safety profiles and are administered differently, which makes them reasonable options for different groups of patients, Johnson continues. Overall, it is important to become familiar with the differences in the toxicity profiles of the drugs to inform optimally selecting between them for patients, Johnson concludes.

Melissa L. Johnson, MD, discusses new drug approvals for EGFR exon 20 insertion mutation–positive non–small cell lung cancer.  


Dr. Johnson on New Drug Approvals for EGFR Exon 20 Insertion Mutation+ NSCLC 

Melissa Johnson, MD, associate director, Lung Cancer Research, Sarah Cannon Research Institute, discusses the phase II BIRCH study, which is examining atezolizumab (Tecentriq) in patients with PD-L1—positive locally advanced or metastatic non–small cell lung cancer (NSCLC).

The ongoing BIRCH trial is enrolling patients irrespective of line of therapy, Johnson explains. However, all patients must have tumors that express PD-L1. Results that were presented at the 2016 ASCO Annual Meeting are of the cohort of patients who received the immunotherapy agent in the frontline setting. 

This marks an important clinical trial, because it demonstrates that PD-L1—positive patients will experience a response rate and progression-free survival that should be, at least, equivalent to rates experienced with chemotherapy. Several patients request treatment with immunotherapy for their lung cancer versus chemotherapy, Johnson explains. 

View more from the 2016 ASCO Annual Meeting

Melissa Johnson, MD, associate director, Lung Cancer Research, Sarah Cannon Research Institute, discusses the phase II BIRCH study, which is examining atezolizumab (Tecentriq) in patients with PD-L1–positive locally advanced or metastatic non–small cell lung cancer (NSCLC).

Melissa Johnson, MD

Articles

Neoadjuvant Immunotherapy in Resectable NSCLC: The NADIM II and AEGAN Trials

The Role of Neoadjuvant Immunotherapy in the Treatment of Resectable NSCLC

Treatment Options for Early-Stage Non-Small Cell Lung Cancer (NSCLC)

Dr. Johnson on New Drug Approvals for EGFR Exon 20 Insertion Mutation+ NSCLC

Dr. Melissa Johnson on Atezolizumab in Patients With NSCLC